Pub Date : 2016-11-01DOI: 10.1515/prilozi-2016-0017
N. Pop-Jordanova, T. Zorcec
Abstract Somatization in children consists of the persistent experience and complaints of somatic distress that cannot be fully explained by a medical diagnosis. Working at the Psychophysiological Department at the University Clinic we are dealing with more than 100 children per year manifesting this kind of disorders. The aim of this article is to summarize some specific characteristics of the somatoform disorder in a group of 243 children, mean age 10.31 (± 2.75) years for both genders, selected randomly. The used psychometric instruments are: CBCL, EPQ for children, and MMPI-201 for mothers. The obtained results showed high scores for somatization, extroversion and accentuated anxiety for children; as well as a typical Hs-Hy personality profile for mothers. The treatment with cognitive-behavior therapy and biofeedback showed very positive outcome.
{"title":"Somatoform Disorders – A Pediatric Experience","authors":"N. Pop-Jordanova, T. Zorcec","doi":"10.1515/prilozi-2016-0017","DOIUrl":"https://doi.org/10.1515/prilozi-2016-0017","url":null,"abstract":"Abstract Somatization in children consists of the persistent experience and complaints of somatic distress that cannot be fully explained by a medical diagnosis. Working at the Psychophysiological Department at the University Clinic we are dealing with more than 100 children per year manifesting this kind of disorders. The aim of this article is to summarize some specific characteristics of the somatoform disorder in a group of 243 children, mean age 10.31 (± 2.75) years for both genders, selected randomly. The used psychometric instruments are: CBCL, EPQ for children, and MMPI-201 for mothers. The obtained results showed high scores for somatization, extroversion and accentuated anxiety for children; as well as a typical Hs-Hy personality profile for mothers. The treatment with cognitive-behavior therapy and biofeedback showed very positive outcome.","PeriodicalId":87202,"journal":{"name":"Prilozi","volume":"29 1","pages":"55 - 62"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75076282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-01DOI: 10.1515/prilozi-2016-0014
M. Stryckers, E. Nagler, W. van Biesen
Abstract As people age, chronic kidney disease becomes more common, but it rarely leads to end-stage kidney disease. When it does, the choice between dialysis and conservative care can be daunting, as much depends on life expectancy and personal expectations of medical care. Shared decision making implies adequately informing patients about their options, and facilitating deliberation of the available information, such that decisions are tailored to the individual’s values and preferences. Accurate estimations of one’s risk of progression to end-stage kidney disease and death with or without dialysis are essential for shared decision making to be effective. Formal risk prediction models can help, provided they are externally validated, well-calibrated and discriminative; include unambiguous and measureable variables; and come with readily applicable equations or scores. Reliable, externally validated risk prediction models for progression of chronic kidney disease to end-stage kidney disease or mortality in frail elderly with or without chronic kidney disease are scant. Within this paper, we discuss a number of promising models, highlighting both the strengths and limitations physicians should understand for using them judiciously, and emphasize the need for external validation over new development for further advancing the field.
{"title":"The Need for Accurate Risk Prediction Models for Road Mapping, Shared Decision Making and Care Planning for the Elderly with Advanced Chronic Kidney Disease","authors":"M. Stryckers, E. Nagler, W. van Biesen","doi":"10.1515/prilozi-2016-0014","DOIUrl":"https://doi.org/10.1515/prilozi-2016-0014","url":null,"abstract":"Abstract As people age, chronic kidney disease becomes more common, but it rarely leads to end-stage kidney disease. When it does, the choice between dialysis and conservative care can be daunting, as much depends on life expectancy and personal expectations of medical care. Shared decision making implies adequately informing patients about their options, and facilitating deliberation of the available information, such that decisions are tailored to the individual’s values and preferences. Accurate estimations of one’s risk of progression to end-stage kidney disease and death with or without dialysis are essential for shared decision making to be effective. Formal risk prediction models can help, provided they are externally validated, well-calibrated and discriminative; include unambiguous and measureable variables; and come with readily applicable equations or scores. Reliable, externally validated risk prediction models for progression of chronic kidney disease to end-stage kidney disease or mortality in frail elderly with or without chronic kidney disease are scant. Within this paper, we discuss a number of promising models, highlighting both the strengths and limitations physicians should understand for using them judiciously, and emphasize the need for external validation over new development for further advancing the field.","PeriodicalId":87202,"journal":{"name":"Prilozi","volume":"21 1","pages":"33 - 42"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75801290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-01DOI: 10.1515/prilozi-2016-0020
S. Marinkovic, Irena Kondova Topuzovska, Z. Milenković, B. Kaeva
Abstract The aim of this study was to identify the participations of the serum coagulations and fibrinolysis factors that contribute to the differential diagnosis of the patients with community-acquired pneumonia (CAP) without effusion, uncomplicated parapneumonic effusion (UCPPE) and complicated parapneumonic effusion (CPPE). The coagulations system is fundamental for the maintenance of homeostasis, and contributes to the inflammatory process responsible for CAP and the parapneumonic effusion. The factors of coagulations and fibrinolysis participate in the cellular proliferation and migration as in the synthesis of the inflammatory mediators. We evaluated the laboratory profile of coagulations and fibrinolysis in the serum of 148 patients with CAP without effusion, 50 with UCPPE and 44 with CPPE. We determined the test of the coagulation cascade which measures the time elapsed from the activation of the coagulation cascade at different points to the fibrin generation. As a consequence, there is an activation of the fibrinolytic system with the increased D-dimer levels measured in the plasma in the three groups. The patients were with mean age ± SD (53,82 ± 17,5) min – max 18–93 years. A significantly higher number of thrombocytes was in the group with CPPE with median 412 × 109/L (rank 323–513 × 109/L). The extended activation of the prothrombin time (aPTT) was significantly higher in the same group of patients with median of 32 sec. (rank 30–35 sec). The mean D-dimer plasma level was 3266,5 ± 1292,3 ng/ml in patients with CPPE, in CAP without effusion 1646,6 ± 1204 ng/ml and in UCPPE 1422,9 ± 970 ng/ml. The coagulations system and the fibrinolysis play important role in the development and pathophysiology of CAP and the parapneumonic effusions.
{"title":"The Role of Serum Coagulation Factors in the Differential Diagnosis of Patients with Pneumonia and Parapneumonic Effusion","authors":"S. Marinkovic, Irena Kondova Topuzovska, Z. Milenković, B. Kaeva","doi":"10.1515/prilozi-2016-0020","DOIUrl":"https://doi.org/10.1515/prilozi-2016-0020","url":null,"abstract":"Abstract The aim of this study was to identify the participations of the serum coagulations and fibrinolysis factors that contribute to the differential diagnosis of the patients with community-acquired pneumonia (CAP) without effusion, uncomplicated parapneumonic effusion (UCPPE) and complicated parapneumonic effusion (CPPE). The coagulations system is fundamental for the maintenance of homeostasis, and contributes to the inflammatory process responsible for CAP and the parapneumonic effusion. The factors of coagulations and fibrinolysis participate in the cellular proliferation and migration as in the synthesis of the inflammatory mediators. We evaluated the laboratory profile of coagulations and fibrinolysis in the serum of 148 patients with CAP without effusion, 50 with UCPPE and 44 with CPPE. We determined the test of the coagulation cascade which measures the time elapsed from the activation of the coagulation cascade at different points to the fibrin generation. As a consequence, there is an activation of the fibrinolytic system with the increased D-dimer levels measured in the plasma in the three groups. The patients were with mean age ± SD (53,82 ± 17,5) min – max 18–93 years. A significantly higher number of thrombocytes was in the group with CPPE with median 412 × 109/L (rank 323–513 × 109/L). The extended activation of the prothrombin time (aPTT) was significantly higher in the same group of patients with median of 32 sec. (rank 30–35 sec). The mean D-dimer plasma level was 3266,5 ± 1292,3 ng/ml in patients with CPPE, in CAP without effusion 1646,6 ± 1204 ng/ml and in UCPPE 1422,9 ± 970 ng/ml. The coagulations system and the fibrinolysis play important role in the development and pathophysiology of CAP and the parapneumonic effusions.","PeriodicalId":87202,"journal":{"name":"Prilozi","volume":"14 1","pages":"81 - 88"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76297441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-01DOI: 10.1515/prilozi-2016-0023
Mile Petrovski
Abstract Regular ultrasound examinations carried out in the second trimester of pregnancy help in detecting many anomalies in the fetal urinary tract. Their percentage ranges from 1% to 3% of all controlled pregnancies. There is a wide spectrum of anomalies that affect the urinary tract, but the most significant are: uretero/hydronephrosis (unilateral or bilateral), kidney agenesis, dysplastic kidney, polycystic and multicystic kidneys, anomalies of ascent, anomalies of kidney rotation or fusion, bladder exstrophy, posterior urethra valve etc. Many of these anomalies do not have impact either on urine flow or on kidney function and hence they can be qualified rather as a condition than as a disease. At the same time, most of the hydronephroses that are seen prenatally are being resolved spontaneously, and they are not detected neither presented postnatally as uretero/hydronephroses of unobstructed type and do not require surgical treatment. Only one tenth of these anomalies are subject to active surgical treatment. Therefore, the assessment of these conditions should be done by a specialized team, who will make adequate therapeutic decisions based on clinical guidelines, as well as will advise the parents on the future clinical implications of the detected anomaly.
{"title":"Diagnostic and Surgical Approach to Prenatally Detected Urinary Tract Anomalies","authors":"Mile Petrovski","doi":"10.1515/prilozi-2016-0023","DOIUrl":"https://doi.org/10.1515/prilozi-2016-0023","url":null,"abstract":"Abstract Regular ultrasound examinations carried out in the second trimester of pregnancy help in detecting many anomalies in the fetal urinary tract. Their percentage ranges from 1% to 3% of all controlled pregnancies. There is a wide spectrum of anomalies that affect the urinary tract, but the most significant are: uretero/hydronephrosis (unilateral or bilateral), kidney agenesis, dysplastic kidney, polycystic and multicystic kidneys, anomalies of ascent, anomalies of kidney rotation or fusion, bladder exstrophy, posterior urethra valve etc. Many of these anomalies do not have impact either on urine flow or on kidney function and hence they can be qualified rather as a condition than as a disease. At the same time, most of the hydronephroses that are seen prenatally are being resolved spontaneously, and they are not detected neither presented postnatally as uretero/hydronephroses of unobstructed type and do not require surgical treatment. Only one tenth of these anomalies are subject to active surgical treatment. Therefore, the assessment of these conditions should be done by a specialized team, who will make adequate therapeutic decisions based on clinical guidelines, as well as will advise the parents on the future clinical implications of the detected anomaly.","PeriodicalId":87202,"journal":{"name":"Prilozi","volume":"37 1","pages":"107 - 113"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79192039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-01DOI: 10.1515/prilozi-2016-0012
S. Honisett, David Pagliaro, K. Tangalakis, B. Kingwell, P. Ebeling, R. Craven, Juliana Antonopillai, V. Apostolopoulos, L. Stojanovska
Abstract Introduction: Independently, hormone therapy and exercise have well-established protective effects on bone parameters. The combined effects of hormone therapy and exercise, however, are less clear. We, therefore, examined the effects of hormone therapy on bone turnover markers in postmenopausal women undergoing regular high intensity exercise. Methods: In a randomised, double blind study, postmenopausal athletes competing at Masters level, received either hormone therapy (50 μg transdermal oestradiol, 5 mg MPA, n = 8) or placebo (n = 7) for 20 weeks. Women were tested before and after treatment for plasma concentrations of oestradiol, FSH, LH, and serum bone formation marker -osteocalcin (OC); and urine bone resorption markers-pyridinoline (PYD) and deoxypyridinoline (DPD). Results: As a result of treatment with hormone therapy there were significant reductions in levels of FSH (73.3 ± 13.7 to 48.6 ± 10.5 mmol/L, p = 0.01) and bone resorption markers (PYD, 81.9 ± 7.7 to 57.8 ± 3.7 nmol/mmol Cr, p = 0.001, and DPD, 18.5 ± 3.1 to 11.8 ± 2.1 nmol/mmol Cr, p = 0.01). Oestradiol and bone formation markers were not significantly altered as a result of hormone therapy. There were no changes to any variables with placebo treatment. Conclusion: Hormone therapy reduced bone resorption, but not bone formation, in postmenopausal athletes. These favorable reductions in bone turnover; therefore, provide an effective treatment in combination with high intensity exercise to further reduce the subsequent risk of osteoporosis and associated fractures.
摘要:激素治疗和运动对骨骼参数的保护作用都是公认的。然而，激素治疗和运动的联合效果尚不清楚。因此，我们研究了激素治疗对绝经后妇女定期进行高强度运动的骨转换标志物的影响。方法:在一项随机、双盲研究中，绝经后参加硕士水平比赛的运动员接受激素治疗(50 μg透皮雌二醇，5 mg MPA, n = 8)或安慰剂(n = 7)，为期20周。在治疗前后检测女性血浆雌二醇、卵泡刺激素、黄体生成素和血清骨形成标志物骨钙素(OC)的浓度;尿骨吸收标志物吡啶啉(PYD)和脱氧吡啶啉(DPD)。结果:激素治疗显著降低FSH(73.3±13.7 ~ 48.6±10.5 mmol/L, p = 0.01)、骨吸收指标(PYD, 81.9±7.7 ~ 57.8±3.7 nmol/mmol Cr, p = 0.001)、DPD, 18.5±3.1 ~ 11.8±2.1 nmol/mmol Cr, p = 0.01)。雌二醇和骨形成标志物并没有因为激素治疗而显著改变。安慰剂治疗没有改变任何变量。结论:激素治疗减少了绝经后运动员的骨吸收，但没有骨形成。这些有利于减少骨转换;因此，提供有效的治疗与高强度运动相结合，以进一步降低骨质疏松症和相关骨折的风险。
{"title":"Hormone Therapy Reduces Bone Resorption but not Bone Formation in Postmenopausal Athletes","authors":"S. Honisett, David Pagliaro, K. Tangalakis, B. Kingwell, P. Ebeling, R. Craven, Juliana Antonopillai, V. Apostolopoulos, L. Stojanovska","doi":"10.1515/prilozi-2016-0012","DOIUrl":"https://doi.org/10.1515/prilozi-2016-0012","url":null,"abstract":"Abstract Introduction: Independently, hormone therapy and exercise have well-established protective effects on bone parameters. The combined effects of hormone therapy and exercise, however, are less clear. We, therefore, examined the effects of hormone therapy on bone turnover markers in postmenopausal women undergoing regular high intensity exercise. Methods: In a randomised, double blind study, postmenopausal athletes competing at Masters level, received either hormone therapy (50 μg transdermal oestradiol, 5 mg MPA, n = 8) or placebo (n = 7) for 20 weeks. Women were tested before and after treatment for plasma concentrations of oestradiol, FSH, LH, and serum bone formation marker -osteocalcin (OC); and urine bone resorption markers-pyridinoline (PYD) and deoxypyridinoline (DPD). Results: As a result of treatment with hormone therapy there were significant reductions in levels of FSH (73.3 ± 13.7 to 48.6 ± 10.5 mmol/L, p = 0.01) and bone resorption markers (PYD, 81.9 ± 7.7 to 57.8 ± 3.7 nmol/mmol Cr, p = 0.001, and DPD, 18.5 ± 3.1 to 11.8 ± 2.1 nmol/mmol Cr, p = 0.01). Oestradiol and bone formation markers were not significantly altered as a result of hormone therapy. There were no changes to any variables with placebo treatment. Conclusion: Hormone therapy reduced bone resorption, but not bone formation, in postmenopausal athletes. These favorable reductions in bone turnover; therefore, provide an effective treatment in combination with high intensity exercise to further reduce the subsequent risk of osteoporosis and associated fractures.","PeriodicalId":87202,"journal":{"name":"Prilozi","volume":"33 1","pages":"15 - 21"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79852149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-01DOI: 10.1515/prilozi-2016-0024
L. Spasevska, V. Janevska, V. Janevski, Biljana Noveska, J. Zhivadinovik
Abstract Pancreas is an extremely rare abdominal localization of the solitary fibrous tumor (SFT). It usually grows asymptomatically for a long time before a diagnosis can be made on the basis of symptoms and/or mechanical complications. Due to the rarity and nonspecific clinical presentation, this entity is diagnostically challenging. We present a 47-year-old man with a history of progressive epigastric pain for the last two weeks, and jaundice, who was admitted to hospital for further investigation. Cystadenocarcinoma was suspected based on the radiologic findings, and a pancreatoduodenectomy was performed. The removed portion of the pancreas contained a 3.5 × 2 × 1.8 cm well-circumscribed, but not encapsulated white tumor mass with smooth cut surface, cystic component and duct dilatation within the tumor and within the adjacent pancreatic tissue. Based on the histology and immunostaining profile, a diagnosis of the solitary fibrous tumor was made. One week post-operatively, the patient died due to surgical complications. Microscopic and immunohistochemical examinations are necessary for accurate diagnosis of cystic SFT of the pancreas. Because there is limited data regarding the biological behavior of SFT with extra-pleural localization the authors recommend clinical follow-up for SFT treatment if the criteria of malignancy are not met.
{"title":"Solitary Fibrous Tumor of the Pancreas: A Case Report and Review of the Literature","authors":"L. Spasevska, V. Janevska, V. Janevski, Biljana Noveska, J. Zhivadinovik","doi":"10.1515/prilozi-2016-0024","DOIUrl":"https://doi.org/10.1515/prilozi-2016-0024","url":null,"abstract":"Abstract Pancreas is an extremely rare abdominal localization of the solitary fibrous tumor (SFT). It usually grows asymptomatically for a long time before a diagnosis can be made on the basis of symptoms and/or mechanical complications. Due to the rarity and nonspecific clinical presentation, this entity is diagnostically challenging. We present a 47-year-old man with a history of progressive epigastric pain for the last two weeks, and jaundice, who was admitted to hospital for further investigation. Cystadenocarcinoma was suspected based on the radiologic findings, and a pancreatoduodenectomy was performed. The removed portion of the pancreas contained a 3.5 × 2 × 1.8 cm well-circumscribed, but not encapsulated white tumor mass with smooth cut surface, cystic component and duct dilatation within the tumor and within the adjacent pancreatic tissue. Based on the histology and immunostaining profile, a diagnosis of the solitary fibrous tumor was made. One week post-operatively, the patient died due to surgical complications. Microscopic and immunohistochemical examinations are necessary for accurate diagnosis of cystic SFT of the pancreas. Because there is limited data regarding the biological behavior of SFT with extra-pleural localization the authors recommend clinical follow-up for SFT treatment if the criteria of malignancy are not met.","PeriodicalId":87202,"journal":{"name":"Prilozi","volume":"7 3‐4","pages":"115 - 120"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/prilozi-2016-0024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72405465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-01DOI: 10.1515/prilozi-2016-0015
D. Goumenos, E. Papachristou, M. Papasotiriou
Abstract The incidence of chronic kidney disease (CKD) in patients with chronic heart failure (CHF) is high as CKD and CHF share underlying risk factors such as arterial hypertension, diabetes mellitus and atherosclerosis. Cardiac failure leads to renal hypoperfusion and dysfunction and then fluid overload and need for aggressive diuretic therapy. However, development of diuretic resistance represents a significant problem in the management of these patients. The role of Renal Replacement Therapy (RRT) is important for patients who do not response to conservative management of fluid overload facilitating the failing heart to restore function. According to the guidelines, venovenous isolated Ultrafiltration (UF) is indicated for patients with refractory congestion not responding to medical therapy with loop diuretics and infusion of dopamine. A systematic review of randomized controlled trials on the effect of UF vs. IV furosemide for decompensated heart failure showed a benefit of UF on total body weight loss and on readmissions due to heart failure in patients with decompensated heart failure and CKD. Peritoneal dialysis (PD) can provide efficient ultrafiltration and sodium extraction in volume overloaded patients followed by decline of hospitalization days, decrease of body weight and improvement of LVEF in patients with refractory heart failure. The continuous draw of ultrafiltrate is followed by a lesser risk of abrupt hypotension and better preservation of the residual kidney function. This represents a significant advantage of PD over intermittent UF by dialysis. In conclusion, application of UF by dialysis and PD is followed by significant total body weight loss, reduced need for hospital readmissions and better quality of life. PD has a higher probability of preservation of residual kidney function and can be used by patients at home.
{"title":"Renal Replacement Therapy in Patients with Heart and Kidney Failure","authors":"D. Goumenos, E. Papachristou, M. Papasotiriou","doi":"10.1515/prilozi-2016-0015","DOIUrl":"https://doi.org/10.1515/prilozi-2016-0015","url":null,"abstract":"Abstract The incidence of chronic kidney disease (CKD) in patients with chronic heart failure (CHF) is high as CKD and CHF share underlying risk factors such as arterial hypertension, diabetes mellitus and atherosclerosis. Cardiac failure leads to renal hypoperfusion and dysfunction and then fluid overload and need for aggressive diuretic therapy. However, development of diuretic resistance represents a significant problem in the management of these patients. The role of Renal Replacement Therapy (RRT) is important for patients who do not response to conservative management of fluid overload facilitating the failing heart to restore function. According to the guidelines, venovenous isolated Ultrafiltration (UF) is indicated for patients with refractory congestion not responding to medical therapy with loop diuretics and infusion of dopamine. A systematic review of randomized controlled trials on the effect of UF vs. IV furosemide for decompensated heart failure showed a benefit of UF on total body weight loss and on readmissions due to heart failure in patients with decompensated heart failure and CKD. Peritoneal dialysis (PD) can provide efficient ultrafiltration and sodium extraction in volume overloaded patients followed by decline of hospitalization days, decrease of body weight and improvement of LVEF in patients with refractory heart failure. The continuous draw of ultrafiltrate is followed by a lesser risk of abrupt hypotension and better preservation of the residual kidney function. This represents a significant advantage of PD over intermittent UF by dialysis. In conclusion, application of UF by dialysis and PD is followed by significant total body weight loss, reduced need for hospital readmissions and better quality of life. PD has a higher probability of preservation of residual kidney function and can be used by patients at home.","PeriodicalId":87202,"journal":{"name":"Prilozi","volume":"87 1","pages":"43 - 47"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77978810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-01DOI: 10.1515/prilozi-2016-0025
M. Peneva, Elizabeta Zjogovska, Sasho Dohchev, S. Stavridis, A. Josifov, M. Srceva, Anton Damevski, Josif Janchulev, Jelka Masin Spasovska, G. Spasovski
Abstract Kidney transplantations have become common surgical procedures that are associated with high success rates. Nevertheless, the detection, accurate diagnosis and timely management of the perioperative surgical complications sometimes require multidisciplinary team approach for some of the complications may result in significant morbidity, risk of graft loss and/or mortality of the recipient. A case of a 24-year old male patient that developed a number of different surgical complications is reported. The complications included venous graft thrombosis, urinary fistula, wound infection, wound dehiscence and a completely exteriorized transplanted kidney. Despite the various complications and, accordingly, a couple of revisions, finally the patient was discharged with a regular kidney function.
{"title":"Successful Kidney Transplantation in a Patient with Multiple Perioperative Renal Transplant Complications. Case Report","authors":"M. Peneva, Elizabeta Zjogovska, Sasho Dohchev, S. Stavridis, A. Josifov, M. Srceva, Anton Damevski, Josif Janchulev, Jelka Masin Spasovska, G. Spasovski","doi":"10.1515/prilozi-2016-0025","DOIUrl":"https://doi.org/10.1515/prilozi-2016-0025","url":null,"abstract":"Abstract Kidney transplantations have become common surgical procedures that are associated with high success rates. Nevertheless, the detection, accurate diagnosis and timely management of the perioperative surgical complications sometimes require multidisciplinary team approach for some of the complications may result in significant morbidity, risk of graft loss and/or mortality of the recipient. A case of a 24-year old male patient that developed a number of different surgical complications is reported. The complications included venous graft thrombosis, urinary fistula, wound infection, wound dehiscence and a completely exteriorized transplanted kidney. Despite the various complications and, accordingly, a couple of revisions, finally the patient was discharged with a regular kidney function.","PeriodicalId":87202,"journal":{"name":"Prilozi","volume":"37 1","pages":"121 - 125"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90893532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-01DOI: 10.1515/prilozi-2016-0027
G. Spasovski
{"title":"What Should be the Appropriate Referral to the Nephrologists – Do we have the Data?","authors":"G. Spasovski","doi":"10.1515/prilozi-2016-0027","DOIUrl":"https://doi.org/10.1515/prilozi-2016-0027","url":null,"abstract":"","PeriodicalId":87202,"journal":{"name":"Prilozi","volume":"41 1","pages":"133 - 134"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82721750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-01DOI: 10.1515/prilozi-2016-0016
M. Sever
Abstract The terminologies of “body size”, “body mass index (BMI)”, “body weight”, “large BMI” and “obesity” are controversial for defining the effects of “adiposity” or “fat excess” on the outcomes of dialysis and transplant patients. However, probably these terminologies will be continued to be used in the future as well, because of being older and simpler terminologies. In the general population obesity is a powerful risk factor for cardiovascular morbidity and mortality, while, it conferred a survival advantage to dialysis patients. However, this may be a oversimplification, since obesity may still be a risk factor in non-sarcopenic hemodialysis patients. Obesity is associated with early post-transplant adverse effects (i.e. delayed graft function, graft failure, wound infections, also transplant costs) and unfavorable graft and patient survival. However, thanks to safer immunosuppressive protocols, recently graft and patient survival is similar in obese as those of the non-obese patients. On the other hand, morbid obesity may still be a cause of unfavorable patient and graft survival. Since obese transplant recipients have better life expectancy as compared to wait-listed hemodialysis patients, they should be transplanted as well, while morbidly obese patients should be asked to lose weight before being placed in the waiting lists.
{"title":"Body Size and Outcomes in Dialysis and Transplant Patients – Does it Matter?","authors":"M. Sever","doi":"10.1515/prilozi-2016-0016","DOIUrl":"https://doi.org/10.1515/prilozi-2016-0016","url":null,"abstract":"Abstract The terminologies of “body size”, “body mass index (BMI)”, “body weight”, “large BMI” and “obesity” are controversial for defining the effects of “adiposity” or “fat excess” on the outcomes of dialysis and transplant patients. However, probably these terminologies will be continued to be used in the future as well, because of being older and simpler terminologies. In the general population obesity is a powerful risk factor for cardiovascular morbidity and mortality, while, it conferred a survival advantage to dialysis patients. However, this may be a oversimplification, since obesity may still be a risk factor in non-sarcopenic hemodialysis patients. Obesity is associated with early post-transplant adverse effects (i.e. delayed graft function, graft failure, wound infections, also transplant costs) and unfavorable graft and patient survival. However, thanks to safer immunosuppressive protocols, recently graft and patient survival is similar in obese as those of the non-obese patients. On the other hand, morbid obesity may still be a cause of unfavorable patient and graft survival. Since obese transplant recipients have better life expectancy as compared to wait-listed hemodialysis patients, they should be transplanted as well, while morbidly obese patients should be asked to lose weight before being placed in the waiting lists.","PeriodicalId":87202,"journal":{"name":"Prilozi","volume":"22 1","pages":"49 - 53"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85825266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：